| Q36074720 | 'Bipolar missed states': the diagnosis and clinical salience of bipolar mixed states |
| Q35111576 | Advances in the pharmacologic treatment of bipolar depression |
| Q34433880 | Antidepressant dosage taken by patients with bipolar disorder: factors associated with irregularity |
| Q44440922 | Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism |
| Q34068875 | Antidepressants in bipolar disorder |
| Q43145175 | Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study |
| Q35089923 | Avoiding drug-induced switching in patients with bipolar depression |
| Q36286401 | Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression |
| Q35101637 | Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options |
| Q35017636 | Bipolar depression: management options |
| Q34675235 | Bipolar spectrum disorders. New perspectives |
| Q60460623 | Clinical indicators for the use of antidepressants in the treatment of bipolar I depression |
| Q35212332 | Concepts in the treatment of bipolar disorder. |
| Q30997997 | Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review |
| Q34676317 | Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology |
| Q35180787 | Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology |
| Q37426143 | Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology |
| Q44451644 | Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations |
| Q38122748 | Impact of psychotropic drugs on suicide and suicidal behaviors |
| Q37624453 | Is evidence sufficient for evidence-based medicine? |
| Q37283773 | Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks |
| Q37165536 | Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression |
| Q35680377 | Pharmacotherapy of bipolar II disorder: a critical review of current evidence |
| Q37627217 | Principle standards and problems regarding proof of efficacy in clinical psychopharmacology |
| Q40278883 | Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years |
| Q50074506 | Psychotropic medications prescribing trends in adolescents: A nationwide population-based study in Taiwan. |
| Q34437976 | Rapid cycling bipolar disease: new concepts and treatments |
| Q45336273 | Revised Korean medication algorithm for bipolar disorder. |
| Q37954416 | State of the art: treatment of bipolar disorders. |
| Q35041599 | The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder |
| Q38040453 | The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states? |
| Q95818126 | The bipolar spectrum |
| Q38764892 | Treating bipolar depression - antidepressants and alternatives: a critical review of the literature |
| Q26770334 | Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches |
| Q35142091 | Treatment of bipolar depression: current status, continued challenges, and the STEP-BD approach |
| Q82351280 | Treatment-resistant bipolar disorder |
| Q35182108 | Which antidepressants flick the switch? |
| Q35024109 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression |
| Q50740011 | [Annual costs of bipolar disorders in Germany]. |
| Q79351350 | [Bipolar depression: a review of current therapeutic strategies] |
| Q80430032 | [Problems of evidence-based medicine in psychopharmacotherapy: problems of evidence grading and of the evidence basis for complex clinical decision making] |